tousled Delflex Neutral pH Generic Name: dextrose monohydrate, sodium chloride, sodium lactate, calcium chloride and magnesium chloride Dosage Form: injection, solution Overview Side Effects Professional Reviews Q & A More Pricing & Coupons DELFLEX Neutral pH Peritoneal Dialysis Solutions with Attached stay safe Exchange Set For Intraperitoneal Administration Only No Latex Description DELFLEX Neutral pH, peritoneal dialysis solutions, (standard, low magnesium and low magnesium/low calcium) are sterile, non-pyrogenic formulations of dextrose and electrolytes in water for injection, USP, for use in peritoneal dialysis. These solutions do not contain antimicrobial agents or additional buffers. In comparison to conventional peritoneal dialysis solutions, DELFLEX Neutral pH solutions are formulated to lower levels of glucose degradation products and provide a neutral pH of 7.0 0.4, which is closer to the physiologic pH. The osmotic and buffer solutions are stored separately and mixed by the patient prior to use. The stay safe Exchange Set utilizes an easy to use dial designed to eliminate the use of clamps and to prevent touch contamination of internal connection components. Composition, calculated osmolarity, pH and ionic concentrations of the mixed solutions are shown in Table 2. Dextrose USP is chemically designated D-glucose monohydrate (C 6 H 12 O 6 H 2 O) a hexose sugar freely soluble in water. The structural formula is shown here. Calcium chloride, USP, is chemically designated calcium chloride dihydrate (CaCl 2 2H 2 O) white fragments or granules freely soluble in water. Magnesium chloride, USP, is chemically designated magnesium chloride hexahydrate (MgCl 2 6H 2 O) colorless flakes or crystals very soluble in water. Sodium lactate solution, USP, is chemically designated (CH 3 CH(OH)COONa), a 60% aqueous solution miscible in water. Sodium chloride, USP, is chemically designated (NaCl), a white, crystalline compound freely soluble in water. Water for injection, USP, is chemically designated (H 2 O). Hydrochloric acid, and sodium hydroxide may be added for pH adjustment. pH is 7.0 0.4. Exposure to temperatures above 25 C (77 F) during transport and storage will lead to minor losses in moisture content. Higher temperatures lead to greater losses. It is unlikely that these minor losses will lead to clinically significant changes within the expiration period. Since the flexible inner bag is compounded from a specific polyvinyl chloride, water may permeate from the inner bag into the outerwrap in quantities insufficient to affect the solution significantly. Solutions in contact with the plastic inner bag can cause certain chemical components of the bag to leach out in very small amounts; however, the safety of the plastic formulation is supported by biological tests for plastic containers. Nominal glucose degradation product (GDP) levels (immediately following sterilization) in DELFLEX Neutral pH solution and DELFLEX solution are reported in Table 1. The clinical relevance of these differences in GDP levels in unknown. *This is the sum [µmol/L] of the various component GDPs including: formaldehyde, acetaldehyde, furaldehyde, glyoxal, methylglyoxal 5-hydroxymethylfurfural (5-HMF), and 3 deoxyglucosone (3DG). Table 2. Composition, Calculated Osmolarity, pH, and Ionic Concentration 2.5 Liter DELFLEX Neutral pH Slideshow Understanding Insulin: What You Need To Know Clinical Pharmacology Peritoneal dialysis is the process of filtering excess water and toxins from the bloodstream through a semi-permeable membrane. This process does not cure the disease, but prevents progression of symptoms. Dialysis for chronic kidney failure is essential to maintain life, unless the patient receives a kidney transplant. A peritoneal dialysis procedure utilizes the peritoneum (lining of the abdomen) as the semi-permeable membrane. The procedure is conducted by instilling peritoneal dialysis solution through a catheter in the abdomen into the peritoneal cavity. Since the peritoneum is heavily supplied with blood vessels, the contact of the solution with the peritoneum causes excess water and toxins in the bloodstream to be drawn across the membrane into the solution. This osmosis and diffusion occurs between the plasma of the patient and the peritoneal dialysis solution. After a period of time called dwell time, the solution is then drained from the patient. This solution does not contain potassium. In situations in which there is a normal serum potassium level or hypokalemia, the addition of potassium chloride (up to a concentration of 4 mEq/L) may be indicated to prevent severe hypokalemia. Addition of potassium chloride should be made after careful evaluation of serum and total body potassium and only under the direction of a physician. Clinical studies have demonstrated that the use of low magnesium solutions resulted in significant increases in serum CO 2 and decreases in serum magnesium levels. The decrease in magnesium levels did not cause clinically significant hypomagnesemia. Indications and Usage DELFLEX peritoneal dialysis solutions are indicated in the treatment of chronic renal failure patients being maintained on peritoneal dialysis when nondialytic medical therapy is judged to be inadequate. Contraindications None known. Warnings Not for Intravenous Injection. Use Aseptic Technique. It is important to mix the buffer (Mini-Bag) and main solutions thoroughly. Administer within 24 hours after mixing. Once solutions are mixed, other prescribed medication(s) may be added prior to administration. After removing the outerwrap, check for minute leaks by squeezing each of the solution bags firmly. If leaks are found, discard the solution because the sterility may be impaired. (A small amount of moisture may be present inside the outerwrap, which is normal condensation from the sterilization process). Peritoneal dialysis should be done with great care, in patients with a number of conditions, including disruption of the peritoneal membrane or diaphragm by surgery or trauma, extensive adhesions, bowel distention, undiagnosed abdominal disease, abdominal wall infection, hernias or burns, fecal fistula or colostomy, tense ascites, obesity, large polycystic kidneys, recent aortic graft replacement, lactic acidosis and severe pulmonary disease. When assessing peritoneal dialysis as the mode of therapy in such extreme situations, the benefits to the patient must be weighed against the possible complications. Solutions containing lactate ion should be used with great care in patients with metabolic or respiratory alkalosis. Lactate should be administered with great care in those conditions in which there is an increased level or an impaired utilization of this ion, such as severe hepatic insufficiency. An accurate fluid balance record must be kept and the weight of the patient carefully monitored to avoid over or under hydration with severe consequences, including congestive heart failure, volume depletion and shock. Excessive use of DELFLEX peritoneal dialysis solution with 4.25% dextrose during a peritoneal dialysis treatment can result in significant removal of water from the patient. Stable patients undergoing maintenance peritoneal dialysis should have routine periodic evaluation of blood chemistries and hematologic factors, as well as other indicators of patient status. Serum calcium levels in patients using low calcium concentrations should be monitored and if found to be low, the peritoneal solution in use should be altered to one with a higher calcium concentration. Precautions General Chronic patients that have been stabilized on peritoneal dialysis therapy should have routine evaluation of electrolyte blood chemistries and hematologic factors measured in order to determine the patient s ongoing condition. DELFLEX peritoneal dialysis solutions do not include potassium. Potassium chloride should only be added under the direction of a physician after careful evaluation of both serum and total body potassium. Significant loss of protein, amino acids and water soluble vitamins may occur during peritoneal dialysis. Replacement therapy should be provided as necessary. Information for Patients Aseptic technique must be used throughout the procedure and at its termination in order to reduce the possibility of infection. The outerwrap should remain intact until time of use. Administer only if the solution is clear, all seals are intact, and there is no evidence of leaking. Do Not Heat In A Microwave Oven. Microwave ovens heat unevenly and can leave hot spots, which can burn the peritoneum. It is important to mix the buffer (Mini-Bag) and main solutions thoroughly. Administer within 24 hours after mixing. Once solutions are mixed, other prescribed medication(s) may be added prior to administration. Disconnect from disc only when knob is in position 4 ( ) to ensure patient connector is sealed. Care should be taken to ensure that there is not any leakage around the catheter, since if not controlled; the leakage can create edema from subcutaneous infiltration of the dialysis solution. This will also create an inaccurate fluid balance measurement. If any leakage is identified do not proceed with infusion and notify your physician. Laboratory Tests Serum electrolytes, magnesium, bicarbonate levels and fluid balance should be periodically monitored. Carcinogenesis, Mutagenesis, Impairment of Fertility Long term animal studies with DELFLEX peritoneal dialysis solutions have not been performed to evaluate the carcinogenic potential, mutagenic potential or effect on fertility. Pregnancy: Teratology Effects Pregnancy Category C. Animal reproduction studies have not been conducted with DELFLEX peritoneal dialysis solutions. It is also not known whether DELFLEX peritoneal dialysis solutions can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. DELFLEX peritoneal dialysis solutions should be given to a pregnant woman only if clearly needed. Nursing Mothers Caution should be exercised when DELFLEX peritoneal dialysis solutions are administered to a nursing woman. Pediatric Use Safety and effectiveness in pediatric patients have not been established. Adverse Reactions Adverse reactions occurring with administration of peritoneal dialysis include mechanical and solution related problems as well as the results of contamination of equipment or improper technique in catheter placement. Abdominal pain, bleeding, peritonitis, subcutaneous infection around a peritoneal catheter, catheter blockage, difficulty in fluid removal, and ileus are among the complications of the procedure. Solution related adverse reactions might include peritonitis, catheter site infection, electrolyte and fluid imbalances, hypovolemia, hypervolemia, hypertension, hypotension, disequilibrium syndrome and muscle cramping. If an adverse reaction does occur, institute appropriate therapeutic procedures according to the patient s needs and conditions, and save the remainder of the fluid in the bag for evaluation if deemed necessary. Dosage and Administration DELFLEX peritoneal dialysis solutions are provided for intraperitoneal administration only. The mode of therapy, frequency of treatment, formulation, exchange volume, duration of dwell, and length of dialysis should be selected by the physician responsible for the treatment of the individual patient. To avoid the risk of severe dehydration or hypovolemia and to minimize the loss of protein, it is advisable to select the peritoneal dialysis solution with lowest level of osmolarity consistent with the fluid removal requirements for that exchange. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Additives may be incompatible. Do not store solutions containing additives. For administration see Directions for Use section. How Supplied DELFLEX peritoneal dialysis solutions are delivered in single-dose flexible bags. All DELFLEX peritoneal dialysis solutions have overfills declared on the bag label. The flexible bags have the capacity for drainage in excess of their stated fill volume for ultrafiltration from the patient. DELFLEX Neutral pH peritoneal dialysis solutions with an attached stay safe Exchange Set is available in flexible bags as shown in Table 2 in the Description section. Storage Conditions Store at 20 C to 25 C (68 F to 77 F); excursions permitted between 15 C and 30 C (between 59 F and 86 F). See USP Controlled Room Temperature. Brief exposure to temperatures up to 40 C (104 F) may be tolerated provided the mean kinetic temperature does not exceed 25 C (77 F); however, such exposure should be minimized. Keep DELFLEX and all medicines out of the reach of children. Fresenius Medical Care Fresenius Medical Care North America 920 Winter Street Waltham, MA 02451 1-800-323-5188 Revised Patent Pending 04/25/2013 Not for Intravenous Injection. Do not microwave. Warm solution as directed by your health care provider. Directions for Use (Aseptic technique is required) Get Ready Clean work surface. Gather supplies: Warmed DELFLEX Neutral pH Peritoneal Dialysis bag with attached stay safe Exchange Set. Povidone iodine prefilled stay safe Cap, a stand alone item provided separately. stay safe Organizer, a stand alone item provided separately (Optional; FMCNA recommends its use). Prescribed medication(s), if ordered by your healthcare provider. Mask. Put on mask. Wash your hands. Ensure that the Extension Set coming from your catheter is clamped. Tear the outerwrap from the slit edge down the length of the inner bags to open. Wipe away any moisture from the solution bags. Some opacity may be observed in the plastic of the bag and/or tubing and is due to moisture absorption during the sterilization process. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually. Inspect DELFLEX Solution Bags: 6. Place the DELFLEX solution set on the work surface. See Figure A. Figure A Position solution bags and drain bag as shown in Figure B. Figure B Firmly squeeze the Main Solution Bag and Mini-Bag to check for leaks. When squeezing the Mini-Bag, the bag should remain firm and no solution should leak into the Main Solution Bag or into the drain line. Do not use DELFLEX Neutral pH solution if: leaks are found the solution bags are damaged solution is cloudy or discolored Red or Blue frangible Cone is broken NOTE: Retain DELFLEX Neutral pH peritoneal dialysis bag sample for manufacturer evaluation and notify your healthcare provider if any of the above defects are found. 7. Turn the blue position indicator on the stay safe disc counter-clockwise until it fits into the cut-out portion of the colored plastic cover on the disc. Remove the colored plastic cover while the indicator is in this position (Position 1: ). Once the cover is removed, do not turn counter-clockwise. See Figure C . (This step is done in preparation to allow the effluent in your peritoneal cavity to drain later on in this procedure). Figure C Mix DELFLEX Neutral pH Solution Important: Mix the Mini-Bag and Main Bag solutions thoroughly. Use the solution within 24 hours after mixing. With the Main Solution Bag laying on the work surface; break the Red frangible Cone by placing the thumb firmly on the Red frangible and pressing down upon it until the end of it breaks off. See Figure D. Figure D Fold the Mini-Bag in half. Firmly squeeze the solution from the Mini-Bag into the Main Solution Bag by pressing the two halves together until the Mini-Bag is empty. See Figure E. Figure E Push down on Main Solution Bag to flush solution back into Mini-Bag. Completely refill the Mini-Bag with solution. See Figure F. Figure F Repeat Step 2 (Figure E) and Step 3 (Figure F) above, at least one time, to make sure that all of the contents of the Mini-Bag have been completely flushed into the Main Solution Bag. Grasp the bottom end of the Main Solution Bag. While keeping the hanger end (top) portion of the bag on the table, flip the bag lengthwise using a back and forth motion to mix the solutions. See Figure G. Repeat this step to mix solution thoroughly. Figure G With the Main Solution Bag still on the table, position it so that the slit in the white slide-lock connector cover is facing up. Fold Mini-Bag in half and squeeze it empty of solution. Slide the folded Mini-Bag into the slit of the white slide-lock connector cover. Ensure that the entire grip area of the Blue frangible is exposed. If the square grip area is not exposed slide the slide-lock connector cover further onto the folded Mini-Bag to expose the grip . See Figure H. Solution may flow back into the Mini-Bag slightly, this is normal. Figure H The solution is now ready for use. Administer DELFLEX Neutral pH Peritoneal Dialysis Solution If you will be adding medication(s): Clean the medication port as instructed by your healthcare provider. Add the medicine(s). Turn the bag upside down several times to mix the medicine(s). Hang the solution bag from the I.V. pole. Place the drain bag at floor level. Break the Blue frangible Cone by placing one hand on the Blue frangible square grip area and placing the other hand on the white slide-lock connector cover and bending it. See Figure I. (If using the Organizer, place the stay safe disc in the Organizer as shown in Figure J ). Figure I Figure J Remove the new stay safe Cap from its package. (The new stay safe Cap is the stand alone item provided to the patient separately). See Figure J . (If using the Organizer place the new stay safe Cap in the left notch of the Organizer. Place the existing cap of the stay safe Extension Set, connected to the patient s catheter, in the other notch of the Organizer. See Figure J ). Aseptically remove the connector cap from the stay safe disc and throw the cap away. See Figure J. Remove the existing cap from the Extension Set connected to the patient s catheter by twisting the connection counter-clockwise. (If using the Organizer, leave the capped end of the Extension Set in the Organizer and twist the Extension Set connector counter-clockwise to remove the set from its cap). Aseptically connect the Extension Set to the connector on the stay safe disc. Twist clockwise to secure the connection. Remove your mask. Do not open the system during exchange. Open the Extension Set clamp to start drain. When patient drain is complete, turn the stay safe disc position indicator to Position 2 ( ). See Figure K . This will start flush from the solution bag to the drain bag. Figure K After approximately 5 seconds turn the stay safe disc position indicator to Position 3 ( ). See Figure L . This will start the patient fill. Figure L When fill is complete, turn the stay safe disc position indicator to Position 4 ( ). See Figure M. This will insert the closure pin of the disc into the Extension Set connector and seal the system. Figure M Close the clamp on the Extension Set. Remove the white protective cover from the new stay safe Cap. Save for later use. Remove the Extension Set from the stay safe disc and attach the new stay safe Cap. Twist clockwise to secure the connection. Seal the disc by attaching the white protective cover from the new stay safe Cap to the disc connector. Twist clockwise to secure the connection and prevent leakage from the used system. Look at the drained fluid for cloudiness. Measure the amount of fluid drained. Throw away the fluid and used set as instructed by your healthcare provider. In case of cloudiness, save the fluid and the used set and immediately contact your healthcare provider. Fresenius Medical Care, triangle logo, stay safe, Delflex, Safe-Lock are trademarks of Fresenius Medical Care Holding, Inc. or its affiliated companies. Principal Display Panel - NDC 49230-188-97 Principal Display Panel - NDC 49230-191-97 Principal Display Panel - NDC 49230-194-97 Principal Display Panel - NDC 49230-197-97 Principal Display Panel - NDC 49230-200-97 Principal Display Panel - NDC 49230-203-97 DELFLEX NEUTRAL PH dextrose monohydrate, sodium chloride, calcium chloride, magnesium chloride, sodium lactate solution Product Information Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:49230-188 Route of Administration INTRAPERITONEAL DEA Schedule Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength DEXTROSE MONOHYDRATE (ANHYDROUS DEXTROSE) DEXTROSE MONOHYDRATE 1.5 g in 100 mL SODIUM CHLORIDE (SODIUM CATION and CHLORIDE ION) SODIUM CHLORIDE 567 mg in 100 mL SODIUM LACTATE (SODIUM CATION and LACTIC ACID) SODIUM LACTATE 353 mg in 100 mL CALCIUM CHLORIDE (CALCIUM CATION and CHLORIDE ION) CALCIUM CHLORIDE 25.7 mg in 100 mL MAGNESIUM CHLORIDE (MAGNESIUM CATION and CHLORIDE ION) MAGNESIUM CHLORIDE 15.2 mg in 100 mL Inactive Ingredients Ingredient Name Strength SODIUM BICARBONATE 29.4 mg in 100 mL WATER SODIUM HYDROXIDE HYDROCHLORIC ACID Packaging # Item Code Package Description 1 NDC:49230-188-97 5 BAG in 1 CARTON 1 2500 mL in 1 BAG Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NDA NDA018883 11/30/1984 DELFLEX NEUTRAL PH dextrose monohydrate, sodium chloride, calcium chloride, magnesium chloride, sodium lactate solution Product Information Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:49230-191 Route of Administration INTRAPERITONEAL DEA Schedule Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength DEXTROSE MONOHYDRATE (ANHYDROUS DEXTROSE) DEXTROSE MONOHYDRATE 2.5 g in 100 mL SODIUM CHLORIDE (SODIUM CATION and CHLORIDE ION) SODIUM CHLORIDE 567 mg in 100 mL SODIUM LACTATE (SODIUM CATION and LACTIC ACID) SODIUM LACTATE 353 mg in 100 mL CALCIUM CHLORIDE (CALCIUM CATION and CHLORIDE ION) CALCIUM CHLORIDE 25.7 mg in 100 mL MAGNESIUM CHLORIDE (MAGNESIUM CATION and CHLORIDE ION) MAGNESIUM CHLORIDE 15.2 mg in 100 mL Inactive Ingredients Ingredient Name Strength SODIUM BICARBONATE 29.4 mg in 100 mL WATER SODIUM HYDROXIDE HYDROCHLORIC ACID Packaging # Item Code Package Description 1 NDC:49230-191-97 5 BAG in 1 CARTON 1 2500 mL in 1 BAG Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NDA NDA018883 11/30/1984 DELFLEX NEUTRAL PH dextrose monohydrate, sodium chloride, calcium chloride, magnesium chloride, sodium lactate solution Product Information Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:49230-194 Route of Administration INTRAPERITONEAL DEA Schedule Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength DEXTROSE MONOHYDRATE (ANHYDROUS DEXTROSE) DEXTROSE MONOHYDRATE 4.25 g in 100 mL SODIUM CHLORIDE (SODIUM CATION and CHLORIDE ION) SODIUM CHLORIDE 567 mg in 100 mL SODIUM LACTATE (SODIUM CATION and LACTIC ACID) SODIUM LACTATE 353 mg in 100 mL CALCIUM CHLORIDE (CALCIUM CATION and CHLORIDE ION) CALCIUM CHLORIDE 25.7 mg in 100 mL MAGNESIUM CHLORIDE (MAGNESIUM CATION and CHLORIDE ION) MAGNESIUM CHLORIDE 15.2 mg in 100 mL Inactive Ingredients Ingredient Name Strength SODIUM BICARBONATE 29.4 mg in 100 mL WATER SODIUM HYDROXIDE HYDROCHLORIC ACID Packaging # Item Code Package Description 1 NDC:49230-194-97 5 BAG in 1 CARTON 1 2500 mL in 1 BAG Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NDA NDA018883 11/30/1984 DELFLEX NEUTRAL PH dextrose monohydrate, sodium chloride, calcium chloride, magnesium chloride, sodium lactate solution Product Information Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:49230-197 Route of Administration INTRAPERITONEAL DEA Schedule Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength DEXTROSE MONOHYDRATE (ANHYDROUS DEXTROSE) DEXTROSE MONOHYDRATE 1.5 g in 100 mL SODIUM CHLORIDE (SODIUM CATION and CHLORIDE ION) SODIUM CHLORIDE 538 mg in 100 mL SODIUM LACTATE (SODIUM CATION and LACTIC ACID) SODIUM LACTATE 409 mg in 100 mL CALCIUM CHLORIDE (CALCIUM CATION and CHLORIDE ION) CALCIUM CHLORIDE 25.7 mg in 100 mL MAGNESIUM CHLORIDE (MAGNESIUM CATION and CHLORIDE ION) MAGNESIUM CHLORIDE 5.08 mg in 100 mL Inactive Ingredients Ingredient Name Strength SODIUM BICARBONATE 29.4 mg in 100 mL WATER SODIUM HYDROXIDE HYDROCHLORIC ACID Packaging # Item Code Package Description 1 NDC:49230-197-97 5 BAG in 1 CARTON 1 2500 mL in 1 BAG Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NDA NDA018883 11/30/1984 DELFLEX NEUTRAL PH dextrose monohydrate, sodium chloride, calcium chloride, magnesium chloride, sodium lactate solution Product Information Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:49230-200 Route of Administration INTRAPERITONEAL DEA Schedule Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength DEXTROSE MONOHYDRATE (ANHYDROUS DEXTROSE) DEXTROSE MONOHYDRATE 2.5 g in 100 mL SODIUM CHLORIDE (SODIUM CATION and CHLORIDE ION) SODIUM CHLORIDE 538 mg in 100 mL SODIUM LACTATE (SODIUM CATION and LACTIC ACID) SODIUM LACTATE 409 mg in 100 mL CALCIUM CHLORIDE (CALCIUM CATION and CHLORIDE ION) CALCIUM CHLORIDE 25.7 mg in 100 mL MAGNESIUM CHLORIDE (MAGNESIUM CATION and CHLORIDE ION) MAGNESIUM CHLORIDE 5.08 mg in 100 mL Inactive Ingredients Ingredient Name Strength SODIUM BICARBONATE 29.4 mg in 100 mL WATER SODIUM HYDROXIDE HYDROCHLORIC ACID Packaging # Item Code Package Description 1 NDC:49230-200-97 5 BAG in 1 CARTON 1 2500 mL in 1 BAG Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NDA NDA018883 11/30/1984 DELFLEX NEUTRAL PH dextrose monohydrate, sodium chloride, calcium chloride, magnesium chloride, sodium lactate solution Product Information Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:49230-203 Route of Administration INTRAPERITONEAL DEA Schedule Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength DEXTROSE MONOHYDRATE (ANHYDROUS DEXTROSE) DEXTROSE MONOHYDRATE 4.25 g in 100 mL SODIUM CHLORIDE (SODIUM CATION and CHLORIDE ION) SODIUM CHLORIDE 538 mg in 100 mL SODIUM LACTATE (SODIUM CATION and LACTIC ACID) SODIUM LACTATE 409 mg in 100 mL CALCIUM CHLORIDE (CALCIUM CATION and CHLORIDE ION) CALCIUM CHLORIDE 25.7 mg in 100 mL MAGNESIUM CHLORIDE (MAGNESIUM CATION and CHLORIDE ION) MAGNESIUM CHLORIDE 5.08 mg in 100 mL Inactive Ingredients Ingredient Name Strength SODIUM BICARBONATE 29.4 mg in 100 mL WATER SODIUM HYDROXIDE HYDROCHLORIC ACID Packaging # Item Code Package Description 1 NDC:49230-203-97 5 BAG in 1 CARTON 1 2500 mL in 1 BAG Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NDA NDA018883 11/30/1984 Labeler - Fresenius Medical Care North America (075684324) Revised: 04/2013 Fresenius Medical Care North America Next User Reviews Print this page Add to My Med List More about lvp solution Side Effects Support Group Pricing & Coupons 0 Reviews Add your own review/rating Drug class: intravenous nutritional products Consumer resources Icodextrin Intravenous (IV) Fluids Icodextrin Intraperitoneal (Advanced Reading) Professional resources Dextrose and Sodium Chloride Injection (FDA) Dextrose in Lactated Ringer's (FDA) Dextrose in Ringer's (FDA) Ringers (FDA) Other brands: Normosol-R , Plasma-Lyte 148 , Extraneal , Delflex , ... +2 more Related treatment guides Dehydration Peritoneal dialysis} FEATURED: CAR-T Cell Therapy Overview Mechanism of Action KTE-C19 Studies KTE-C19 Cancer Targets Adverse Events Manufacturing Drug Status Rx Availability Prescription only C Pregnancy Category Risk cannot be ruled out N/A CSA Schedule Not a controlled drug Manufacturer Baxter International Inc. Drug Class Intravenous nutritional products Related Drugs intravenous nutritional products cysteine , Novamine , Intralipid , fat emulsion , ProSol Dehydration Normosol-R , Plasma-Lyte 148 , Isolyte S , More... Lvp solution Rating No Reviews - Be the first! No Reviews - Be the first! Not Rated - Be the first!} } exercise session
a reasonably large Delflex Neutral pH sports
EmoticonEmoticon